Belarus Launches Cervical Cancer Prevention Campaign with HPV Vaccine
Belarus has launched a significant public health initiative to combat cervical cancer. The Ministry of Health has secured the Secolin vaccine, a recombinant bivalent vaccine against HPV types 16 and 18, which are responsible for almost 80% of cervical cancer cases. This vaccine will be available to 11-year-old girls from October, marking a crucial step in early prevention.
Dr. Alia Daskevich, deputy chief physician for epidemiology, announced the vaccine's availability. The vaccination scheme involves two doses, administered intramuscularly in the shoulder. Notably, girls of older age who have not been vaccinated will also be considered if their parents have contacted the department or clinics. This move aims to ensure that as many individuals as possible benefit from this preventive measure.
Cervical cancer is the second most common gynecological oncological disease in Belarus, with around 300-350 deaths annually. Early detection results in a 92% survival rate for five years or more, but late-stage prognosis is much worse. The HPV vaccine, which provides immunity against HPV infections that can lead to cervical cancer and other HPV-related diseases, is expected to significantly reduce these figures.
The Secolin vaccine will be included in the National Calendar of Preventive Vaccinations from 2025, ensuring its long-term availability and accessibility. This initiative underscores Belarus' commitment to improving public health and reducing the impact of cervical cancer.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
